Active Ingredient: Asciminib
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral
80 - 80 mg
From 40 To 40 mg 2 time(s) per day every day
The recommended dose is 40 mg twice daily at approximately 12-hour intervals.
If a dose is missed by less than 6 hours, it should be taken and the next dose should be taken as scheduled.
If a dose is missed by more than approximately 6 hours, it should be skipped and the next dose should be taken as scheduled.
Treatment with asciminib should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.
The starting dose is 40 mg twice daily, while the reduced dose is 20 mg twice daily. The dose can be modified based on individual safety and tolerability as shown in the following table. Asciminib should be permanently discontinued in patients unable to tolerate a dose of 20 mg twice daily.
Asciminib dose modification schedule for the management of adverse reactions:
| Adverse reaction | Dose modification |
|---|---|
| Thrombocytopenia and/or neutropenia | |
| ANC <1.0 × 109/l and/or PLT <50 × 109/l | Withhold asciminib until resolved to ANC ≥1 × 109/l and/or PLT ≥50 × 109/l. If resolved: • Within 2 weeks: resume at starting dose. • After more than 2 weeks: resume at reduced dose. For recurrent severe thrombocytopenia and/or neutropenia, withhold asciminib until resolved to ANC ≥1 × 109/l and PLT ≥50 × 109/l, then resume at reduced dose. |
| Asymptomatic amylase and/or lipase elevation | |
| Elevation >2.0 x ULN | Withhold asciminib until resolved to <1.5 x ULN. • If resolved: resume at reduced dose. If events reoccur at reduced dose, permanently discontinue. • If not resolved: permanently discontinue. Perform diagnostic tests to exclude pancreatitis. |
| Non-haematological adverse reactions | |
| Grade 3 or higher1 adverse reactions | Withhold asciminib until resolved to grade 1 or lower. • If resolved: resume at a reduced dose. • If not resolved: permanently discontinue. |
ANC: absolute neutrophil count; PLT: platelets; ULN: upper limit of normal
1 Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03.
The asciminib tablets should be swallowed whole with a glass of water and should not be broken, crushed or chewed.
The tablets should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
